8-K: Skinvisible Reports Licensee Quoin Pharmaceuticals Sees Success in Netherton Syndrome Clinical Studies

Skinvisible Pharmaceuticals announces significant achievements through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment, potentially leading to the first FDA approval for a formulation using Skinvisible's Invisicare delivery technology.

Summary

• Skinvisible Pharmaceuticals announced positive developments from its licensee, Quoin Pharmaceuticals, regarding the treatment of Netherton Syndrome.
• Quoin's product, QRX003, utilizes Skinvisible's Invisicare technology.
• Key developments include FDA clearance for a 'whole body' study at Northwestern University and significant clinical improvements in open label and pediatric studies.
• One subject's disease classification improved from 'severe' to 'mild' after six weeks of dosing.
• No adverse events or safety concerns have been reported in Quoin's ongoing clinical studies.
• Studies have expanded internationally to the UK, Ireland, and Saudi Arabia.
• Skinvisible is entitled to a $5 million milestone payment and ongoing royalties from sales upon successful FDA or EU approval of QRX003.
• Skinvisible is actively seeking strategic partnerships to develop topical and transdermal Invisicare formulations for various indications, including obesity therapies.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the progress of Quoin Pharmaceuticals in clinical trials, the potential for FDA approval, and the milestone payment and royalties Skinvisible is set to receive. The lack of reported adverse events and the expansion of studies internationally further contribute to the positive sentiment.

Positives

• Quoin Pharmaceuticals has achieved FDA clearance for a Netherton Syndrome study.
• Clinical studies show significant improvements in Netherton Syndrome patients using QRX003.
• No adverse events or safety concerns have been reported in clinical studies.
• Quoin has expanded its Netherton Syndrome studies internationally.
• Skinvisible is positioned to receive a $5 million milestone payment and royalties upon regulatory approval of QRX003.
• Skinvisible is actively pursuing strategic partnerships to expand the applications of its Invisicare technology.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results could differ materially from those projected due to various risk factors, including those discussed in Skinvisible's SEC filings.
• There is no guarantee that QRX003 will receive FDA or EU approval.
• The market acceptance and size of potential markets for Skinvisible's products are uncertain.

Future Outlook

Skinvisible anticipates a significant milestone with its licensee potentially receiving the first FDA approval for a formulation using its Invisicare delivery technology and remains committed to supporting Quoin's efforts to bring this groundbreaking treatment to Netherton Syndrome patients worldwide. Skinvisible continues to actively seek strategic partnerships with pharmaceutical and biotech companies to bring topical and transdermal Invisicare formulations to the market including the first transdermal obesity therapies and explore broader applications of its delivery platform with other small molecules.

Management Comments

• 'We anticipate a significant milestone with our licensee potentially receiving the first FDA approval for a formulation using our Invisicare delivery technology,' said Terry Howlett, President and CEO of Skinvisible.
• Terry Howlett stated that this validates Skinvisible's strategy of developing innovative topical and transdermal therapeutics for other indications.
• Terry Howlett noted that Skinvisible remains committed to supporting Quoin's efforts to bring this groundbreaking treatment to Netherton Syndrome patients worldwide.

Industry Context

This announcement highlights the growing interest in innovative drug delivery technologies for treating rare skin diseases. The success of Quoin Pharmaceuticals with Skinvisible's Invisicare technology could pave the way for broader applications of this technology in other therapeutic areas. Other companies in the topical and transdermal drug delivery space include companies such as Amgen, Novartis and Johnson & Johnson.

Comparison to Industry Standards

• The progress of QRX003 in Netherton Syndrome treatment can be compared to other rare disease drug development programs, which often face challenges in clinical trials and regulatory approvals.
• The potential $5 million milestone payment and ongoing royalties for Skinvisible are typical for licensing agreements in the pharmaceutical industry, but the actual value will depend on the commercial success of QRX003.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals have successfully developed and commercialized treatments for rare diseases, setting a benchmark for Quoin Pharmaceuticals to follow.

Stakeholder Impact

• Shareholders may benefit from the potential milestone payment and royalties Skinvisible could receive.
• Employees may benefit from the company's growth and expansion.
• Netherton Syndrome patients may benefit from a new treatment option.
• Strategic partners may benefit from collaborating with Skinvisible on innovative drug delivery technologies.

Next Steps

• Quoin Pharmaceuticals will continue its clinical studies of QRX003 for Netherton Syndrome.
• Quoin Pharmaceuticals will seek FDA and EU approval for QRX003.
• Skinvisible will continue to support Quoin's efforts to bring QRX003 to market.
• Skinvisible will actively seek strategic partnerships to develop topical and transdermal Invisicare formulations for various indications.

Key Dates

Keywords

Skinvisible, Quoin Pharmaceuticals, Invisicare, Netherton Syndrome, QRX003, FDA approval, Clinical studies, Licensing agreement, Drug delivery, Topical, Transdermal, Pharmaceuticals